|

Breast Cancer Clinical Trials in Indianapolis, IN

46 recruiting studies within 50 miles

Phase
Trial Phase Dist.
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/A<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3<1 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3<1 mi
Exercise in Metastatic Breast Cancer: EMBodyN/A<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3<1 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPhase 3<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3<1 mi
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer SurgeryPhase 1<1 mi
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With ChemotherapyPhase 2<1 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3<1 mi
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast CancerPhase 1<1 mi
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3<1 mi
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Phase 1/2<1 mi
NearWave Optical Molecular MonitoringN/A<1 mi
Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast CancerPhase 2<1 mi
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesPhase 1/2<1 mi
Low Dose Aspirin for the Prevention of Postpartum Related Breast CancerPhase 2<1 mi
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast CancersPhase 2<1 mi
Study of 68Ga-R10602Phase 1<1 mi
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPhase 3<1 mi
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPhase 1/2<1 mi
Phase IIIb Study of Ribociclib + ET in Early Breast CancerPhase 3<1 mi
ATEMPT 2.0: Adjuvant T-DM1 vs THPhase 2<1 mi
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerPhase 2<1 mi
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPhase 1<1 mi
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Phase 3<1 mi
HER2 Vaccine for Locally Advanced Breast CancerPhase 1<1 mi
Study of LP-184 in Patients With Advanced Solid TumorsPhase 1/2<1 mi
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerPhase 3<1 mi
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3<1 mi
A Study of LY4337713 in Participants With FAP-Positive Solid TumorsPhase 1<1 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsN/A<1 mi
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast CancerPhase 1<1 mi
Increasing Germline Genetic Testing for Patients With CancerN/A<1 mi
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsPhase 1/2<1 mi
A Study of LY4175408 in Participants With Advanced CancerPhase 1<1 mi
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsPhase 1<1 mi
A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerPhase 1/2<1 mi
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or BevacizumabPhase 1<1 mi
TTX-080 HLA-G Antagonist in Subjects With Advanced CancersPhase 1<1 mi
A Study of Sigvotatug Vedotin in Advanced Solid TumorsPhase 1<1 mi
Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsPhase 1<1 mi
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationPhase 311 mi
Study of Oral MRT-2359 in Selected Cancer PatientsPhase 1/246 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.